17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
CAS: 16590-41-3
Ref. 3D-FC46032
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen | ||
250mg | Ausgelaufen |
Produktinformation
- Naltrexone
- (1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-on
- (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one
- (5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
- (5alpha)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one
- 1-N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynormorphinone
- 16590-41-3
- Depotrex
- En 1639
- En 1639A
- Mehr Synonyme anzeigen
- Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-
- Morphinan-6-one, 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-
- N-Cyclopropylmethylnoroxymorphone
- Naltrel
- Naltrexon
- Naltrexona
- Nemexin
- ReVia
- Trexonil
- Um 792
- Vivitrex
- Vivitrol
Naltrexone is a drug that is used in the pharmacological treatment of bowel disease. It is an opioid antagonist and has been shown to inhibit binding of opioid receptor agonists in vitro. Naltrexone blocks the effect of opioids by binding to the same receptors, blocking their ability to produce a response. The efficacy of naltrexone for treating bowel disease has been demonstrated in clinical trials with an intention-to-treat population and using the Mayo Clinic activity index.